Biotech Values

[iwfal]

"I definitely think it's time to think along other lines of treatment, and that's finally becoming more widespread," says Robert Mahley, president of the nonprofit J. David Gladstone Institutes, San Francisco, and a leading Alzheimer's researcher. "Big pharma has had all its eggs in [the amyloid] basket, and is starting to worry about that."

That is clearly the thesis of the writer, but she provides little in the way of data - are there more papers on up-stream causes? More up-stream drugs in early trials?

She seems more to have an agenda than reporting on facts.

Some elderly people who die with the disease don't have senile plaques.

Is this the same disease? (One of the key methodologies for advancement of modern medicine has been to divide up 'one disease' by etiology)